The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) gave its thumbs-up to eight new medicines including two vaccines ... and Daiichii Sankyo’s antibody-drug ...

Demand for its COVID vaccine has been waning since the pandemic, while adoption of its RSV shot - its second approved product- has been slower than expected, forcing Moderna to cut costs.

Analysts expressed concerns about R&D spending, vaccine sales uncertainties ... s growth to offset Datroway’s shortfall. Daiichi Sankyo’s Q3 FY2024 results reflect strong performance in ...

TOKYO & BASKING RIDGE, N.J., January 13, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property ...